Publications
179 results found
Michael DR, Davies TS, Jack AA, et al., 2021, Daily supplementation with the Lab4P probiotic consortium induces significant weight loss in overweight adults, Scientific Reports, Vol: 11
<jats:title>Abstract</jats:title><jats:p>This 9-month randomised, parallel, double-blind, single-centre, placebo-controlled study (PROBE, ISRCTN18030882) assessed the impact of probiotic supplementation on bodyweight. Seventy overweight Bulgarian participants aged 45–65 years with BMI 25–29.9 kg/m<jats:sup>2</jats:sup> received a daily dose of the Lab4P probiotic comprising lactobacilli and bifidobacteria (50 billion cfu/day). Participants maintained their normal diet and lifestyle over the duration of the study. The primary outcome was change from baseline in body weight and secondary outcomes included changes in waist circumference, hip circumference and blood pressure. A significant between group decrease in body weight (3.16 kg, 95% CI 3.94, 2.38, <jats:italic>p</jats:italic> < 0.0001) was detected favouring the probiotic group. Supplementation also resulted in significant between group decreases in waist circumference (2.58 cm, 95% CI 3.23, 1.94, <jats:italic>p</jats:italic> < 0.0001) and hip circumference (2.66 cm, 95% CI 3.28, 2.05, <jats:italic>p</jats:italic> < 0.0001) but no changes in blood pressure were observed. These findings support the outcomes of a previous shorter-term Lab4P intervention study in overweight and obese participants (PROMAGEN, ISRCTN12562026). We conclude that Lab4P has consistent weight modulation capability in free-living overweight adults.</jats:p>
Ianiro G, Mullish BH, Hvas CL, et al., 2021, Impact of SARS-CoV-2 vaccines on donor recruitment for faecal microbiota transplantation, The Lancet Gastroenterology and Hepatology, ISSN: 2468-1253
Allegretti JR, Kassam Z, Hurtado J, et al., 2021, Impact of fecal microbiota transplantation with capsules on the prevention of metabolic syndrome among patients with obesity, HORMONES-INTERNATIONAL JOURNAL OF ENDOCRINOLOGY AND METABOLISM, ISSN: 1109-3099
Huus KE, Frankowski M, Pučić-Baković M, et al., 2021, Changes in IgA-targeted microbiota following fecal transplantation for recurrent Clostridioides difficile infection, Gut Microbes, Vol: 13, Pages: 1-12, ISSN: 1949-0976
Mullish BH, Michael DR, McDonald JA, et al., 2021, Identifying the factors influencing outcome in probiotic studies in overweight and obese patients: host or microbiome?, Gut, Vol: 70, Pages: 225-226
Forlano R, Mullish BH, Maurice JB, et al., 2021, NAFLD: Time to apply quantitation in liver biopsies as endpoints in clinical trials, Journal of Hepatology, Vol: 74, Pages: 241-242, ISSN: 0168-8278
Forlano R, Mullish BH, Nathwani R, et al., 2020, Non-Alcoholic Fatty Liver Disease and Vascular Disease, Current Vascular Pharmacology, Vol: 19, Pages: 269-279, ISSN: 1570-1611
<jats:sec><jats:title /><jats:p>Non-Alcoholic Fatty Liver Disease (NAFLD) represents an increasing cause of liver diseaseworldwide. However, notably, the primary cause of morbidity and mortality in patients with NAFLD iscardiovascular disease (CVD), with fibrosis stage being the strongest disease-specific predictor. It isglobally projected that NAFLD will become increasingly prevalent, especially among children andyounger adults. As such, even within the next few years, NAFLD will contribute considerably to theoverall CVD burden.</jats:p></jats:sec><jats:sec><jats:title /><jats:p>In this review, we discuss the role of NAFLD as an emerging risk factor for CVD. In particular, thisarticle aims to provide an overview of pathological drivers of vascular damage in patients with NAFLD.Moreover, the impact of NAFLD on the development, severity and the progression of subclinical andclinical CVD will be discussed. Finally, the review illustrates current and potential future perspectivesto screen for CVD in this high-risk population.</jats:p></jats:sec>
Innes AJ, Ghani R, Mullish BH, et al., 2020, O105. Faecal microbiota transplant (FMT) can reduce the high NRM associated with multi-drug resistant organism (MDRO) colonisation prior to allogeneic HCT., The 46th Annual Meeting of the European Society for Blood and Marrow Transplantation, Publisher: Springer Nature [academic journals on nature.com], Pages: 122-122, ISSN: 0268-3369
Baunwall SMD, Lee MM, Eriksen MK, et al., 2020, Faecal microbiota transplantation for recurrent Clostridioides difficile infection: An updated systematic review and meta-analysis, EClinicalMedicine, Vol: 29-30, Pages: 100642-100642, ISSN: 2589-5370
Michael DR, Jack AA, Masetti G, et al., 2020, A randomised controlled study shows supplementation of overweight and obese adults with lactobacilli and bifidobacteria reduces bodyweight and improves well-being, Scientific Reports, Vol: 10
Ovadia C, Perdones-Montero A, Fan HM, et al., 2020, Ursodeoxycholic acid enriches intestinal bile salt hydrolase-expressing Bacteroidetes in cholestatic pregnancy, Scientific Reports, Vol: 10
Smith PJ, 2020, GI highlights from the literature, Gut, Vol: 69, Pages: 2256-2257, ISSN: 0017-5749
Miguens Blanco J, Selvarajah U, Liu Z, et al., 2020, Identification of New Associations Between Psoriatic Arthritis and the Gut Microbiota. the Mi-PART, a Phenomic Study, ACR Convergence 2020, Publisher: Wiley, ISSN: 2326-5205
Martinez-Gili L, McDonald JAK, Liu Z, et al., 2020, Understanding the mechanisms of efficacy of fecal microbiota transplant in treating recurrent Clostridioides difficile infection and beyond: the contribution of gut microbial-derived metabolites, Gut Microbes, Vol: 12, Pages: 1810531-1810531, ISSN: 1949-0976
Allegretti JR, Kelly CR, Grinspan A, et al., 2020, Inflammatory Bowel Disease Outcomes Following Fecal Microbiota Transplantation for Recurrent C. difficile Infection, Inflammatory Bowel Diseases, ISSN: 1078-0998
<jats:title>Abstract</jats:title> <jats:sec> <jats:title>Background</jats:title> <jats:p>Recurrent Clostridioides difficile infection (CDI) in patients with inflammatory bowel disease (IBD) is a clinical challenge. Fecal microbiota transplantation (FMT) has emerged as a recurrent CDI therapy. Anecdotal concerns exist regarding worsening of IBD activity; however, prospective data among IBD patients are limited.</jats:p> </jats:sec> <jats:sec> <jats:title>Methods</jats:title> <jats:p>Secondary analysis from an open-label, prospective, multicenter cohort study among IBD patients with 2 or more CDI episodes was performed. Participants underwent a single FMT by colonoscopy (250 mL, healthy universal donor). Secondary IBD-related outcomes included rate of de novo IBD flares, worsening IBD, and IBD improvement—all based on Mayo or Harvey-Bradshaw index (HBI) scores. Stool samples were collected for microbiome and targeted metabolomic profiling.</jats:p> </jats:sec> <jats:sec> <jats:title>Results</jats:title> <jats:p>Fifty patients enrolled in the study, among which 15 had Crohn’s disease (mean HBI, 5.8 ± 3.4) and 35 had ulcerative colitis (mean partial Mayo score, 4.2 ± 2.1). Overall, 49 patients received treatment. Among the Crohn’s disease cohort, 73.3% (11 of 15) had IBD improvement, and 4 (26.6%) had no disease activity change. Among the ulcerative colitis cohort, 62% (22 of 34) had IBD improvement, 29.4% (11 of 34) had no change, and 4% (1 of 34) experienced a de novo flare. Alpha diversity significantly increased post-FMT, and ulcerative colitis patients became more similar to the donor than Crohn’s disease patients (P = 0.04).</jats:p>
Craven LJ, McIlroy JR, Mullish BH, et al., 2020, Letter: Intestinal microbiota transfer – Updating the nomenclature to increase acceptability, Alimentary Pharmacology and Therapeutics, Vol: 52, Pages: 1622-1623, ISSN: 0269-2813
This article is linked to Lai et al paper. To view this article, visit https://doi.org/10.1111/apt.15116
Allegretti JR, Kelly CR, Grinspan A, et al., 2020, Outcomes of Fecal Microbiota Transplantation in Patients With Inflammatory Bowel Diseases and Recurrent Clostridioides difficile Infection, Gastroenterology, Vol: 159, Pages: 1982-1984, ISSN: 0016-5085
Mullish BH, 2020, FMT for the Treatment of Obesity, Metabolic Syndrome and NAFLD, The 6 Ds of FMT: A Primer for Clinicians from Decision to Discharge and Beyond, Editors: Allegretti, Kassam, ISBN: 9781630917500
Ghani R, Mullish BH, 2020, Decision – Considerations for use of fecal microbiota transplantation in special patient populations, The 6 Ds of FMT: A Primer for Clinicians from Decision to Discharge and Beyond, Editors: Allegretti, Kassam, Publisher: Slack Inc, ISBN: 9781630917500
Gupta S, Mullish BH, Allegretti JR, 2020, Fecal microbiota transplantation: the evolving risk landscape, American Journal of Gastroenterology, ISSN: 0002-9270
Fecal microbiota transplantation (FMT) has been recommended in clinical guidelines for the treatment for recurrent Clostridioides difficile infection (CDI). However, it is considered investigational by most regulatory agencies. As the adoption of FMT increased from a small group of CDI experts alone to more widespread use, there has been a corresponding increase in concern regarding potential risk. FMT is largely considered a safe procedure, though risks described range from mild gastrointestinal symptoms to serious infection. Currently, there is variability in how ‘FMT’ is characterized specifically with regards to testing approach, which, in turn, impacts the risk profile. This has been highlighted by the rare cases of multidrug-resistant organisms, Shiga toxin-producing E. coli and enteropathogenic E. coli recently reported, where these organisms were not screened. These cases have prompted additional screening mandates from the FDA, which has maintained its policy of enforcement discretion for the use of FMT for CDI not responding to standard therapy. Here, we examine the evolving risk landscape of FMT.
Alexander JL, Mullish BH, 2020, A Guide to the Gut Microbiome and its Relevance to Critical Care, British Journal of Nursing, Vol: 29, Pages: 1106-1112, ISSN: 0966-0461
<jats:p> Although it is well-established that particular bacteria may cause gastroenteritis and other infections when present in the gut, it is only recently that scientists have made significant inroads into understanding the huge number of other bacteria and additional microbes that live within the gastrointestinal tract, referred to as the gut microbiome. In particular, it is now recognised that bacteria within the gut microbiome have a wide variety of roles in maintaining different aspects of human health, and that disturbances of these bacteria may potentially cause or contribute to a number of different medical conditions, including particular infections, certain cancers, and chronic conditions, including inflammatory bowel disease. Moreover, there is increasing awareness that these bacteria help determine how the body responds to medication, including antibiotics and chemotherapy. There has been growing interest in different approaches to alter the gut microbiome as a novel approach to medical therapy. This article provides an overview of the importance of the gut microbiome, with a particular focus on critical care. </jats:p>
Mullish BH, Ghani R, McDonald JAK, et al., 2020, Reply to Woodworth, et al, Clinical Infectious Diseases, ISSN: 1058-4838
Forlano R, Mullish BH, Mukherjee SK, et al., 2020, In-hospital mortality is associated with inflammatory response in NAFLD patients admitted for COVID-19, PLOS ONE, Vol: 15, Pages: e0240400-e0240400
Forlano R, Mullish B, Mukherjee S, et al., 2020, 450 - In-hospital mortality is associated with inflammatory response in NAFLD patients admitted for COVID-19, Hepatology, Vol: 72, Pages: 282A-283A, ISSN: 0270-9139
Allegretti JR, Kelly C, Grinspan AM, et al., 2020, S0650 Fecal Microbiota Transplantation Decolonizes C. difficile in Patients With Inflammatory Bowel Disease and Concomitant C. difficile Infection, Publisher: Ovid Technologies (Wolters Kluwer Health), Pages: S326-S326, ISSN: 0002-9270
McIlroy JR, Mullish BH, Goldenberg SD, et al., 2020, Intestinal microbiome transfer, a novel therapeutic strategy for COVID-19 induced hyperinflammation?, Clinical Immunology, Vol: 218, Pages: 108542-108542, ISSN: 1521-6616
Ianiro G, Mullish BH, Kelly CR, et al., 2020, Reorganisation of faecal microbiota transplant services during the COVID-19 pandemic, Gut, Vol: 69, Pages: 1555-1563, ISSN: 0017-5749
<jats:p>The COVID-19 pandemic has led to an exponential increase in SARS-CoV-2 infections and associated deaths, and represents a significant challenge to healthcare professionals and facilities. Individual countries have taken several prevention and containment actions to control the spread of infection, including measures to guarantee safety of both healthcare professionals and patients who are at increased risk of infection from COVID-19. Faecal microbiota transplantation (FMT) has a well-established role in the treatment of <jats:italic>Clostridioides difficile</jats:italic> infection. In the time of the pandemic, FMT centres and stool banks are required to adopt a workflow that continues to ensure reliable patient access to FMT while maintaining safety and quality of procedures. In this position paper, based on the best available evidence, worldwide FMT experts provide guidance on issues relating to the impact of COVID-19 on FMT, including patient selection, donor recruitment and selection, stool manufacturing, FMT procedures, patient follow-up and research activities.</jats:p>
Segal JP, Mullish BH, Quraishi MN, et al., 2020, Letter: faecal microbiota transplantation for IBS, Alimentary Pharmacology & Therapeutics, Vol: 52, Pages: 556-557, ISSN: 0269-2813
Forlano R, Mullish BH, Giannakeas N, et al., 2020, High-Throughput, Machine Learning–Based Quantification of Steatosis, Inflammation, Ballooning, and Fibrosis in Biopsies From Patients With Nonalcoholic Fatty Liver Disease, Clinical Gastroenterology and Hepatology, Vol: 18, Pages: 2081-2090.e9, ISSN: 1542-3565
Smith PJ, 2020, GI highlights from the literature, Gut, Vol: 69, Pages: 1533-1534, ISSN: 0017-5749
This data is extracted from the Web of Science and reproduced under a licence from Thomson Reuters. You may not copy or re-distribute this data in whole or in part without the written consent of the Science business of Thomson Reuters.